ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, has told DirectorsTalk that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed.
Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said:“We are delighted to have received such support from our existing shareholders and new investors in this placing to fund our pivotal Phase III Lupuzor™ trial. Having recently announced that we have commenced dosing our first Lupus patients in the US, we look forward to providing regular updates on the trial through this year and 2017.”